Patients
A total of 1639 patients were considered eligible. Among them, 1171
patients met the exclusion criteria: 31 with an inadequate dose
reduction of DOACs, 315 with afternoon procedures, 289 with adjunctive
ablation procedures, and 861 with an age older than 65 years old. We
thus finally studied 468 patients: 113 (24.1%) patients with apixaban,
130 (27.8%) with dabigatran, 144 (30.8%) with edoxaban, and 81
(17.3%) with rivaroxaban. The baseline characteristics of the patients
included are summarized in Table 1.